<DOC>
	<DOCNO>NCT02190578</DOCNO>
	<brief_summary>To determine efficacy improve rapid diagnostic test use venous whole blood fingerstick whole blood . The clinical performance Reveal G4 Rapid HIV-1 Antibody Test determine compare result patient infected status HIV-1 ( human immunodeficiency virus type 1 ) . The study consist single one-hour visit , time blood sample collect tested investigational device ( Reveal G4 ) FDA approve comparator assay detection HIV-1 antibody .</brief_summary>
	<brief_title>Clinical Performance Reveal G4 Rapid HIV-1 Antibody Test</brief_title>
	<detailed_description>This clinical trial multi-center study assess performance characteristic rapid vitro diagnostic assay , Reveal G4 Rapid HIV-1 Antibody Test ( Reveal G4 ) . Specifically , objective study determine sensitivity specificity Reveal G4 finger stick venous whole blood , relative FDA approve reference assay detection HIV-1 antibody . Approximately 1500-2000 subject total enrol study across site , three different study population . Population 1 comprise least 500 subject population risk infection HIV . Population 2 comprise least 500 subject know HIV positive individual . Population 3 comprise least 500 subject population low risk HIV infection . Reveal G4 use test fingerstick whole blood venous whole blood sample study subject . For enrolled subject Populations 1 3 , unknown HIV antibody status , plasma sample prepared venous whole blood sample also test algorithm FDA-approved assay detection HIV-1 antibody . For Population 2 subject know HIV-positive individual , result previous HIV test obtain subject ' medical record . The sensitivity specificity Reveal G4 determine fingerstick venous whole blood relative HIV-1 antibody status determine algorithm FDA-approved assay . The primary analysis involve comparison Reveal G4 result anti-HIV-1 sample matrix ( fingerstick whole blood venous whole blood ) subject 's HIV-1 antibody status determine FDA-approved assay . Based , sensitivity specificity Reveal G4 determine correspond two-sided 95 % confidence interval fingerstick venous whole blood .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>All subject must least 18 year age , able sign consent form , complete risk assessment questionnaire , provide require blood sample : fingerstick sample ( 1 drop ) , venous whole blood sample ( 1 K2 EDTA tube ) . Population 1 Individuals risk HIV infection ( n ≥ 500 ) Subjects must meet least one risk factor infection HIV Population 2 Known HIV1 positive individual ( n ≥ 500 ) Subjects must know HIVpositive individual ( previous positive HIV test result ) Population 3 Individuals low risk HIV infection ( n ≥ 500 ) Subjects must risk factor infection HIV Subjects meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>